Skip to content

Dexmedetomidine Effect on Mitochondrial Function

The Protective Effect of the α2-agonist Dexmedetomidine on Mitochondrial Structure and Function for Children With Non-cyanotic Congenital Heart Defects Having Cardiac Surgery: A Randomized Controlled Trial.

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02299063
Enrollment
36
Registered
2014-11-24
Start date
2014-11-30
Completion date
2019-12-31
Last updated
2018-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complication of Anesthesia, Ischaemia-reperfusion Injury

Keywords

Mitochondria, Dexmedetomidine, Heart Defects, Congenital

Brief summary

The investigators hypothesize that in addition to a known sympatholytic effect, intraoperative dexmedetomidine reduces adverse changes in mitochondrial function and structure attenuating ischaemia-reperfusion and end-organ injury for children with non cyanotic congenital heart defects having corrective heart surgery.

Detailed description

PICO: For children with non cyanotic congenital heart defects having corrective heart surgery (P) does intraoperative dexmedetomidine (I) reduce real-time changes in mitochondrial function and content (O) compared with children not receiving dexmedetomidine (C). The study drug (dexmedetomidine or placebo) will be mixed in a standardized syringe of 4mcg/mL for active syringes or 50mL 0.9% sodium chloride for placebo. Blinded syringes will be prepared by the Research Support Pharmacy. Administration is via the existing central venous line. A bolus dose of 0.125mL/kg (0.5 mcg/kg dexmedetomidine) infused over 10 minutes will be administered, followed by a continuous infusion for the duration of the surgery. The dexmedetomidine/placebo continuous infusion (CI) dose will run at 0.15mL/kg/hr (0.6 mcg/kg/hr dexmedetomidine). Blood samples will be obtained from each child at three points in the operating room: 1) after the induction of anesthesia, 2) at the first separation from CPB (prior to administration of blood products), and 3) at the end of the surgery. Samples obtained will be analyzed for mitochondrial function and morphology, total cellular mitochondrial biomass, and mitochondrial deoxyribonucleic acid (mtDNA) damage: 1. After isolating lymphocytes, we will use high content imaging (HCI) to assess mitochondrial function and morphology. The lymphocytes will be stained with tetramethylrhodamine methyl ester (TMRM), which stains mitochondria in proportion to mitochondrial membrane potential, giving a metric for mitochondrial function. In addition, the cells will be stained with MitoTracker Green®, which can be used to assess mitochondrial morphology. Mitochondrial morphology will be quantified in a non-biased fashion using a mathematical image analysis algorithm. 2. After extraction of genomic DNA, total cellular mitochondrial biomass and mitochondrial DNA damage will be measured using traditional and long-patch quantitative polymerase chain reaction (PCR). Myocardial tissue will be also collected prior to closure of the atriotomy. Samples will be placed into 3% buffered glutaraldehyde at the time of biopsy, and imaging of mitochondrial structure using electron microscopy will be performed.

Interventions

DRUGDexmedetomidine

A bolus dose of 0.5 mcg/kg infused over 10 minutes will be administered, followed by a continuous infusion for the duration of the surgery at 0.6 mcg/kg/hr.

DRUG0.9% NaCl

Sponsors

The Hospital for Sick Children
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
3 Months to 36 Months
Healthy volunteers
No

Inclusion criteria

* aged between 3 - 36 months * having primary corrective heart surgery

Exclusion criteria

* recent surgery (\< 3 months) * previous chemotherapy * previous transfusion of blood products * neurodevelopmental disorders (including Trisomy 21) * supplemental oxygen requirement (\< 3 months) * asthma requiring regular therapy * obstructive sleep apnea * the presence of concurrent infection or inflammation * a known allergy to dexmedetomidine hydrochloride

Design outcomes

Primary

MeasureTime frameDescription
Mitochondrial function (use high content imaging (HCI)IntraoperativeThe primary outcomes for mitochondria will be grouped into mitochondrial function, morphology, content and mtDNA damage.

Secondary

MeasureTime frameDescription
Creatinine level (Marker of acute renal injury)Postoperative day 1Marker of acute renal injury
Cardiac function (Left ventricular ejection fraction measured by trans-thoracic echocardiography)Postoperative day 1Left ventricular ejection fraction measured by trans-thoracic echocardiography
Inotropes and vasopressors (Duration and dose of inotropes and vasopressors after surgery)Postoperative day 1Duration and dose of inotropes and vasopressors after surgery

Other

MeasureTime frameDescription
Analgesic effects (Morphine equivalent dose of narcotics consumed)Perioperative (from induction of anesthesia for 24 hours)Morphine equivalent dose of narcotics consumed
Sedative effects (Duration of intubation)Perioperative (from induction of anesthesia for 24 hours)Duration of intubation.

Countries

Canada

Contacts

Primary ContactJames D O'Leary, MBBCh
james.oleary@sickkids.ca(416) 813-1500

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026